Organon & Co
NYSE:OGN
Organon & Co
Operating Income
Organon & Co
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Organon & Co
NYSE:OGN
|
Operating Income
$1.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Organon & Co's Operating Income?
Operating Income
1.3B
USD
Based on the financial report for Dec 31, 2023, Organon & Co's Operating Income amounts to 1.3B USD.
What is Organon & Co's Operating Income growth rate?
Operating Income CAGR 5Y
-15%
Over the last year, the Operating Income growth was -25%. The average annual Operating Income growth rates for Organon & Co have been -23% over the past three years , -15% over the past five years .